Summary: During the 2017-2018 influenza season, we estimate that influenza vaccination reduced the risk of medically-attended influenza by 38% and prevented 7 million illnesses, 4 million medical visits, 109,000 hospitalizations, and 8,000 deaths in the United States. 
Introduction
The 2017-2018 influenza season in the United States was a high severity season [1, 2] . Circulation of influenza viruses was widespread for an extended period throughout the country. Influenza A(H3N2) viruses predominated, but influenza A(H1N1)pdm09 and B viruses also circulated [2] . The Centers for Disease Control and Prevention (CDC) has estimated that there were 49 million influenza illnesses, 960,000 hospitalizations, and 79,000 influenza-associated deaths during 2017-2018, the highest morbidity and mortality since the 2009 pandemic [3] .
Influenza vaccination is the primary strategy to prevent influenza illness and its complications. Recent reports estimate that 42% of the U.S. population was vaccinated against influenza during the 2017-2018
season [4, 5] ; and the mid-season estimates of the effectiveness of influenza vaccine were 36% against all influenza A and B virus infections and 25% against A(H3N2) virus infections [6] . Here we report endof-season vaccine effectiveness (VE) and apply it with vaccine coverage to estimate the number of influenza-associated illnesses, medical visits, hospitalizations, and deaths prevented by influenza vaccination.
Methods

Influenza vaccine composition
The [7] .
Influenza vaccine effectiveness
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Effectiveness of 2017-2018 influenza vaccination for the prevention of outpatient medically-attended influenza illness was determined through the U.S. Influenza Vaccine Effectiveness (Flu VE) Network, which has been described in detail previously [8] [9] [10] [11] . Briefly, study staff recruited, consented, and enrolled patients aged ≥6 months seeking outpatient care for acute respiratory illness (including cough) within 7 days of symptom onset at 52 participating health care facilities in five research sites in Michigan, Pennsylvania, Texas, Washington, and Wisconsin. Patients who received an antiviral medication in the 7 days before enrollment or who were enrolled in the prior 14 days were not eligible.
Study staff collected a combined nasal and throat swab from patients aged ≥2 years or a nasal swab only from children aged <2 years. Reverse-transcription polymerase chain reaction (RT-PCR) was used to detect influenza viruses, including subtype and lineage. All diagnostic labs used primers and probes from CDC and passed proficiency testing. Staff interviewed patients for demographic data, current health status, symptoms, and reported receipt of 2017-2018 influenza vaccine. We looked for
International Classification of Diseases codes assigned to medical encounters in the year prior to enrollment to determine whether participants had a pre-existing health condition associated with increased risk of severe influenza [12, 13] .
For all U.S. Flu VE Network sites, a participant's vaccination status was based on documented receipt of 2017-2018 influenza vaccine in electronic immunization records (medical records, state immunization systems, and employee health records). In addition, at four sites (excluding Wisconsin), we considered adults aged ≥18 years vaccinated if they reported timing and place of vaccination without documented receipt. We excluded children (aged 6 month-8 years) who were partially vaccinated. We used a testnegative design to estimate VE, contrasting the odds of influenza vaccination among participants with
RT-PCR-positive influenza (cases) to the odds of vaccination among participants who were negative for influenza (controls) using a logistic regression model [14] . We estimated VE, and 95% confidence 7 intervals (CI), against any influenza and by influenza virus type or subtype in separate models and stratified models by participant age (6 months-4 years, 5-17 years, 18-49 years, 50-64 years, and ≥65 years). We adjusted all logistic regression models, a priori, for network site, calendar time (in bi-week increments), participant age, and high-risk status.
The VE Network study was approved by institutional review boards at each participating site and CDC.
Estimates of influenza-associated outcomes
The methods for estimating age-specific influenza burden have been detailed elsewhere and estimates from the 2017-2018 season are available at https://www.cdc.gov/flu/about/burden/estimates.htm [3, 15] . This method uses mathematical multipliers to calculate illnesses, medical visits, and deaths from data on hospitalized cases reported through the Influenza Hospitalization Surveillance Network (FluSurv-NET), as illustrated in Supplemental Figure 1 . For this analysis, we restricted burden estimates to those aged ≥6 months. We further estimated the burden by influenza virus type and subtype using virologic distributions observed in the U.S. Flu VE Network patients for illnesses and medical visits and the distributions observed in FluSurv-NET to estimate hospitalizations and deaths for each (sub)type [16] . As data on influenza A subtype was missing for 60% of FluSurv-NET patients with influenza A virus infection, we used multiple imputation (70 imputations) to estimate the rate of hospitalization for each subtype, including patient age, surveillance site, and admission time period (October-December, January, February, or March-May) in the imputation model. 
Influenza vaccine coverage
Influenza-associated outcomes prevented by vaccination
We estimated the effect of seasonal influenza vaccination on disease burden using a mathematical compartmental model, stratified by age group [17] . We began the model with all members of the U.S.
population unvaccinated and susceptible to influenza. Each month the susceptible population was divided, based on observed data, into those who became infected (using data on estimated illness), those who were vaccinated and protected against influenza (using data on vaccine coverage and effectiveness), and those who remained susceptible to infection. Each month we estimated age-specific rates of illness (and medical visits, hospitalizations, and deaths) by dividing the observed monthly count by the prior month's susceptible population. Using these rates among susceptible persons, we estimated the number of outcomes that would have occurred in the same population without influenza vaccination. We calculated the prevented outcomes as the difference between outcomes in the absence of vaccination and those estimated under current levels of vaccination [15, 18, 19] .
Estimates of VE in adult outpatients and inpatients during 2017-2018 were similar in the U.S., thus we assumed that VE estimates from the U.S. Flu VE Network applied to all influenza outcomes and were also constant across the season [20] . We applied (sub)type-specific VE estimates to the (sub)type specific models.
We estimated the number needed to vaccinate (NNV) to prevent one influenza-associated hospitalization by dividing the number of vaccinated individuals by hospitalizations prevented by 9 vaccination. When VE 95% confidence intervals included the null, the undefined value of NNV was indicated as >999,999. Our estimates of NNV were stratified by age group.
We used a Monte Carlo algorithm to estimate a 95% credible interval (CrI) around the estimates, incorporating uncertainty in each data input. Briefly, we chose a value at random from the assumed distribution for each of the model inputs (Supplemental Table 1 ) and calculated the estimated prevented outcome and repeated the process 5,000 times. Distributions for VE and vaccine coverage were truncated at 0.
Sensitivity analysis for vaccine coverage
Because missing responses to the influenza vaccination question were more common in the BRFSS with missing responses were unvaccinated; and reducing coverage by 3-17% to account for overestimation by self-report [21] [22] [23] [24] [25] .
Results
Among the population eligible for influenza vaccination, aged ≥6 months, we estimated there were 47.9 million illnesses, 22.1 million medical visits, 953,000 hospitalizations, and 79,400 deaths associated with influenza in 2017-2018. Adults aged ≥65 years accounted for 15% of illnesses, but 70% and 90% of all hospitalizations and deaths, respectively.
Influenza A(H3N2) was associated with the highest rates of illness, affecting 9% of children aged 6 months-4 years and 15% of adults aged 50-64 years ( Figure 1 and Supplemental Table 2 ). After applying these rates to the U.S. population, influenza A(H3N2) was associated with an estimated 28.4 million illnesses, 13.0 million medical visits, 587,000 hospitalizations, and 49,000 deaths overall (Supplemental Table 3 ). Influenza A(H1N1)pdm09 virus infections were less common, with 4.6 million illnesses.
Influenza B virus infections accounted for 15.7 million illnesses, 32% of all influenza illnesses. Among those enrolled in the U.S. Flu VE Network, 42% of influenza-positive case-patients and 53% of influenza-negative controls were vaccinated against influenza (Supplemental Table 5 ). Of the vaccinated participants aged <65 years with known vaccine type, 97% received quadrivalent inactivated influenza vaccine (IIV4) and 3% received trivalent inactivated influenza vaccine (IIV3). Of vaccinated adults aged ≥65 years with known vaccine type, 51% received high dose IIV3, 47% received standard dose IIV4 or IIV3, and 2% received adjuvanted IIV3.
VE against any influenza A or B virus infection was 38% (95% CI: 31-43%) after adjustment for study site, age, high-risk condition, and calendar time (Figure 2 ; Supplemental Table 5 ). The VE estimates against any influenza virus infection varied by age group and were statistically significant in all age groups except for people aged ≥65 years ( Figure 2 ). The adjusted VE against A(H3N2) was 22% (95% CI: 12-31%)
overall, but also varied by age and was only statistically significant in children aged 6 months-4 years.
The adjusted VE against A(H1N1)pdm09 was 62% (95% CI: 50-71%) and VE against influenza B was 50% (95% CI: 41-57%).
Vaccine prevented burden
We estimated that influenza vaccination prevented 7.1 million (95% CrI: 5.4 million-9.3 million) illnesses and 3.7 million (95% CrI: 2.8 million-4.9 million) medical visits ( Table 2 ). Prevented illnesses included 2.3 million illnesses due to A(H3N2) viruses and 1.4 million illnesses due to A(H1N1)pdm09 viruses; 48% and 70% of which, respectively, were prevented among children (Supplemental table 6 ). Additionally, over 3 million illnesses from influenza B viruses were prevented with vaccination.
Overall, an estimated 109,000 (95% CrI: 38,900-231,000) hospitalizations were prevented by vaccination; or 10% (95% CrI: 4-19%) of expected hospitalizations (Table 2) . However, the percent of expected hospitalizations prevented by vaccination varied by age group, from a low of 7% (95% CrI: 4-10%) in adults aged 18-49 years, who had the lowest vaccine coverage, to a high of 41% (95% CrI: 33-47%) in children aged 6 months-4 years, who had high vaccine coverage and the highest VE ( Figure 3 ).
The burden of influenza-associated hospitalizations was greatest in adults aged ≥65 years and our model estimated that influenza vaccination prevented approximately 65,000 influenza-associated hospitalizations (95% CrI: 0-185,000; 9% of expected, 95% CrI: 0-21%) in this age group despite lower VE compared with other age groups. Using the estimated vaccine coverage and the overall prevented 12 hospitalizations, we estimate that 462 people (95% CrI: 162, >999,999) aged ≥65 years needed to be vaccinated for each influenza-associated hospitalization prevented (Table 3) .
Finally, an estimated 8,000 (95% CrI: 1,100-21,000) influenza-associated deaths were prevented by vaccination (9% of expected deaths, overall; 95 % CrI: 1-20%). Influenza vaccination prevented an estimated 39% (95% CrI: 30-45%) of influenza-related mortality in children aged 6 months-4 years.
In sensitivity analysis, all credible intervals for estimates of prevented hospitalizations using various vaccine coverage scenarios overlapped with the credible intervals using the reported 2017-2018 coverage (Supplemental Table 7 ).
Discussion
During the 2017-2018 season, currently available influenza vaccines reduced the risk of any influenza associated medically-attended illness by 38% and A(H3N2) associated illness by 22%. When modeled with burden and vaccine coverage, we estimated that influenza vaccination prevented 7.1 million illnesses, 109,000 hospitalizations, and 8,000 deaths related to influenza. In young children, aged 6 months-4 years, the benefits of vaccination were greatest with 41% of all expected hospitalizations prevented by vaccination. VE against A(H1N1)pdm09 and B viruses was greater in all age groups than for A(H3N2); and accordingly, the benefit of vaccination against these viruses was greater than against A(H3N2) viruses. Nevertheless, our results suggest that currently available vaccines provided substantial benefit during a season with high rates of influenza associated medical visits, hospitalizations, and deaths.
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The population benefit of influenza vaccination in our model depends on burden, vaccine effectiveness, however, the population benefit of seasonal influenza vaccination would be greater if indirect effects were present and considered in the model [33, 34] . circulating A(H3N2) viruses were poorly inhibited by antisera raised against egg-adapted viruses used for production of the majority of influenza vaccines in the U.S. [2] . The higher VE against A(H3N2) viruses that we observed in young children may suggest that the immune response to the current A(H3N2) vaccine virus differs by age; this deserves more attention as young children had higher VE despite being vaccinated with egg-based vaccines. Among older adults, egg adaptation of A(H3N2) vaccine viruses may have contributed to reduced effectiveness despite increasing use of high dose vaccine, which was shown previously to be more effective than standard dose influenza vaccines in previous A(H3N2) predominant seasons [36] . Even with reduced VE among older adults, vaccination still prevented one influenzarelated hospitalization for every 462 people vaccinated. More broadly, we need to better understand the factors that contribute to differences in VE to improve influenza vaccines.
Our estimates of the effect of vaccination rely on large, multi-state research and surveillance platforms, but there are limitations to the available data. First, multipliers are used to scale surveillance data to national burden estimates. Data to calculate the multipliers often lag by two years; thus, we use multipliers measured during previous influenza seasons. Any changes in testing practices, care-seeking behavior, or disease severity patterns that occurred during 2017-2018 would not be reflected in the multipliers. Our estimates of the effect of vaccination will be revised on CDC websites as data are updated. Second, we imputed subtype-specific hospitalization rates because subtyping was not performed systematically in FluSurv-Net. Third, our model does not currently account for possible waning effectiveness of influenza vaccination over the season [37] [38] [39] [40] [41] [42] [43] . The current literature is inconsistent about the amount of waning that occurs; however, including any amount of waning effectiveness in the model would have reduced our estimated population benefit. Fourth, vaccination coverage estimates from self-report and telephone surveys have limitations, including lower response rates and possible inaccuracy of vaccination status [21-25, 44, 45] . All results of our sensitivity analysis fell within the credible intervals using reported coverage. Fifth, as we assumed that influenza vaccination would not increase the risk of infection, our credible intervals are truncated at 0 and thus skewed in favor of a population benefit. Finally, the role of genetic and antigenic diversity on the VE and estimated population benefit deserves further investigation and full antigenic and genetic characterization of specimens from the US Flu VE Network is ongoing towards this effort.
Our results highlight the large burden of influenza-associated illnesses, medical visits, hospitalizations, and deaths during 2017-2018 and the value of current vaccines to reduce the burden of disease, even with a VE of 38% against influenza A and B viruses and 22% against A(H3N2) viruses. Given the substantial burden of influenza-associated illness, efforts to improve influenza vaccines are imperative.
An A(H3N2) vaccine component with improved effectiveness could substantially reduce the number of influenza-associated hospitalizations among older adults [46] . Several studies have suggested that vaccines with a higher dose of antigen may offer protective advantages over standard dose inactivated influenza vaccines in older adults [36, 47, 48] . Also, it is possible that vaccine viruses not propagated in 
